ESR1 and breast carcinoma: Despite such efforts, only a handful of these agents have been granted approval by the FDA/EMA for the treatment of ER+ advanced breast cancer, primarily due to dose-limiting toxicity and consequent use of subtherapeutic dosages that result in incomplete pathway inhibition.